McKesson Corporation (MCK) Stock

NYSE
HealthcareMedical Distribution Website

MCK has an Alpha Score of 52 out of 100 (weak), computed on Nov 12, 2026 from 3 of 4 sub-scores. 26 members of Congress disclosed 75 trades in MCK since 2014: 44 purchases and 31 sales, most recently Rick Larsen (purchase, Jul 8, 2026). 7 of the hedge funds AlphaScala tracks reported MCK in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $365.59M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 13, 2026. Its trailing P/E ratio is 26.4 and its net margin 1.1% (key statistics as of Nov 12, 2026).

$1102.81
+2.39%
Last price
Source: Finnhub
Alpha Score
52
Weak

What is MCK's Alpha Score?

How it works →

Alpha Score of 52 reflects moderate overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
85
Strong
Value
26
Poor
Quality
56
Moderate

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 12, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded McKesson Corporation (MCK)?

Members
26
Disclosed trades
75
Purchases
44
Sales
31

Most recent: Rick Larsen (purchase, Jul 8, 2026); records start Feb 6, 2014.

PoliticianTrade dateTypeAmount
Rick Larsen
D-WA · House
2026-07-08purchase$1k – $15k
Jonathan Jackson
D-IL · House
2026-06-15sale$1k – $15k
Lizzie Fletcher
D-TX · House
2026-04-08partial sale$1k – $15k
Alan Armstrong
R-OK · Senate
2026-03-27purchase$1k – $15k
Markwayne Mullin
R-OK · Senate
2026-02-04purchase$15k – $50k
Markwayne Mullin
R-OK · Senate
2026-01-05purchase$15k – $50k
Gil Cisneros
D-CA · House
2025-12-19sale$1k – $15k
Jared Moskowitz
D-FL · House
2025-12-02purchase$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 12, 2026. Senate records here end Nov 4, 2026; later Senate trades are not included.

Every member of Congress who traded MCK, with filing lags →

Which hedge funds own MCK?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
D.E. Shaw
David Shaw
484K$365.59M+807%
Citadel
Ken Griffin
460K$347.89M+512%
Renaissance Technologies
Jim Simons (founder)
195K$166.63M-46%
Millennium Management
Israel Englander
101K$76.42M+76%
Point72
Steve Cohen
72K$54.36MNEW
Bridgewater Associates
Ray Dalio
70K$53.16M+4%
Lone Pine Capital
Steve Mandel
58K$43.71M-85%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are McKesson Corporation insiders buying or selling?

SEC Form 4 filings
90 days to Nov 13, 2026
Buys
0
Sells
4
Net $
-$2.2M
Unique insiders
2
DateInsiderRoleTypeSharesValue
Nov 5, 26Fraga FranciscoEVP, CIO and CTOSELL650$717K
Nov 4, 26Fraga FranciscoEVP, CIO and CTOSELL600$630K
Oct 15, 26Fraga FranciscoEVP, CIO and CTOSELL800.491$797K
Sep 8, 26Rutledge Napoleon B JrSVP, Controller & CAOSELL111$99K
Aug 10, 26Lerman Bradley EDirectorSELL301$269K
Mar 2, 26Lau MicheleEVP and Chief Legal OfficerSELL2.7K$2.7M
Feb 19, 26Martinez MariaDirectorSELL349$328K
Feb 17, 26Smith Leann BEVP & Chief HR OfficerSELL190$180K
Feb 11, 26Lau MicheleEVP and Chief Legal OfficerSELL303$283K
Feb 6, 26Rutledge Napoleon B JrSVP, Controller & CAOSELL328$313K

SEC Form 4 filings as of Nov 13, 2026

See cluster-buy signals across all tickers →

What are MCK's key statistics?

P/E Ratio
26.38
EPS (TTM)
38.86
Dividend Yield
0.54%
Beta
0.25
Net Margin
1.12%
ROE
39.43%
Debt / Equity
1.45
52W High
$1121.50
52W Low
$723.68

Key statistics as of Nov 12, 2026

How does MCK's valuation compare with the Healthcare sector?

MetricMCKHealthcare medianCompanies in median
P/E ratio26.428.4131
Net margin1.12%3.58%199
Return on equity39.43%2.96%226
Dividend yield (payers)0.54%1.37%57

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 16, 2026). P/E excludes loss-making companies.

MCK price chart

Powered by TradingView

What does McKesson Corporation do?

McKesson Corporation is a leading diversified healthcare services company specializing in pharmaceutical distribution and supply chain management solutions. It operates primarily through key segments including North American Pharmaceutical, which sources and distributes branded, generic, and specialty drugs to retail pharmacies, hospital networks, and healthcare providers; Oncology & Multispecialty, focusing on provider and specialty distribution growth; Prescription Technology Solutions, offering third-party logistics and technology services for pharmacies; and Medical-Surgical Solutions, supplying medical products and equipment to healthcare facilities. McKesson also engages in pharmaceutical wholesale in Canada and provides technology solutions enhancing access and efficiency in healthcare delivery. As one of three dominant players accounting for over 90% of the U.S. pharmaceutical wholesale market, alongside peers like Cencora and Cardinal Health, it partners with manufacturers, providers, pharmacies, and governments to ensure safe, timely, and cost-effective delivery of medicines and services. Founded in 1833 and headquartered in Irving, Texas, McKesson Corporation plays a critical role in the global healthcare ecosystem.

CEO
Mr. Brian S. Tyler Ph.D.
Employees
43,000
Market Cap
$123.99B
Ask about MCKAI research agent